Placental growth factor mediates aldosterone-dependent vascular injury in mice

Journal of Clinical Investigation

Volumn 120, Issue 11, 2010, Pages 3891-3900

  Jaffe, Iris Z ^a   Newfell, Brenna G ^a   Aronovitz, Mark ^a   Mohammad, Najwa N ^a   McGraw, Adam P ^a   Perreault, Roger E ^a   Carmeliet, Peter ^b,c   Ehsan, Afshin ^a   Mendelsohn, Michael E ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; MINERALOCORTICOID RECEPTOR; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TRANSCRIPTION REGULATION;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PREGNANCY PROTEINS; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 78049438298     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI40205     Document Type: Article

References (57)

1. Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. RALES Investigators. N Engl J Med. 1999; 341(10):709-717.
2. Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321. (Pubitemid 36384098)
3. Barter PJ, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-2122.
4. Bots ML, et al. Torcetrapib and carotid intimamedia thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370(9582):153-160.
5. Nissen SE, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304-1316. (Pubitemid 46513296)
6. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE. Circulation. 2008;118(24):2506-2514.
7. Vergeer M, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008;118(24):2515-2522.
8. Duriez P. CETP inhibition. Lancet. 2007; 370(9603):1882-1883.
9. Funder JW. The off-target effects of torcetrapib. Endocrinology. 2009;150(5):2024-2026.
10. Rogerson FM, Fuller PJ. Mineralocorticoid action. Steroids. 2000;65(2):61-73.
11. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104(4):545-556.
12. Davis C, Fischer J, Ley K, Sarembock IJ. The role of inflammation in vascular injury and repair. J Thromb Haemost. 2003;1(8):1699-1709.
13. Wakabayashi K, Suzuki H, Sato T, Iso Y, Katagiri T, Takeyama Y. Eplerenone suppresses neointimal formation after coronary stent implantation in swine. Int J Cardiol. 2006;107(2):260-266. (Pubitemid 43075243)
14. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation. 2001;104(4):467-472. (Pubitemid 32678279)
15. Rocha R, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283(5):H1802-H1810.
16. Van Belle E, et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res. 1995;29(1):27-32.
17. Lonn E, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103(7):919-925. (Pubitemid 32183795)
18. Lombes M, Farman N, Bonvalet JP, Zennaro MC. Identification and role of aldosterone receptors in the cardiovascular system. Ann Endocrinol (Paris). 2000;61(1):41-46. (Pubitemid 30246167)
19. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96(6):643-650.
20. Caprio M, et al. Functional Mineralocorticoid Receptors in Human Vascular Endothelial Cells Regulate ICAM-1 Expression and Promote Leukocyte Adhesion. Circ Res. 2008;102(11):1359-1367.
21. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol. 2007;27(4):799-805. (Pubitemid 46606709)
22. Luttun A, et al. Revascularization of ischemic tissues by PGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Med. 2002;8(8):831-840.
23. Kodama Y, et al. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol. 2006;48(1):43-50.
24. Heeschen C, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA. 2004;291(4):435-441.
25. Khurana R, et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation. 2005;111(21):2828-2836.
26. Pilarczyk K, et al. Placenta growth factor expression in human atherosclerotic carotid plaques is related to plaque destabilization. Atherosclerosis. 2008;196(1):333-340.
27. Iafrati MD, et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nature Med. 1997;3(5):545-548.
28. Karas RH, et al. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999; 96(26):15133-15136.
29. Karas RH, et al. A complex role for the progesterone receptor in the response to vascular injury. J Clin Invest. 2001;108(4):611-618.
30. Karas RH, et al. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res. 2001;89(6):534-539.
31. Pare G, et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res. 2002;90(10):1087-1092.
32. Sullivan TR Jr, et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest. 1995;96(5):2482-2488.
33. van de Wal RM, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2006; 106(3):367-372.
34. Vasan RS, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351(1):33-41.
35. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100(2):158-173.
36. Lombes M, Binart N, Oblin ME, Joulin V, Baulieu EE. Characterization of the interaction of the human mineral-ocorticosteroid receptor with hormone response elements. Biochem J. 1993;292(pt 2):577-583.
37. Derfoul A, Robertson NM, Lingrel JB, Hall DJ, Litwack G. Regulation of the human Na/KATPase beta1 gene promoter by mineralocorticoid and glucocorticoid receptors. J Biol Chem. 1998; 273(33):20702-20711.
38. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8(12):942-956.
39. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161(5):1773-1781.
40. Ganz P, Davies PF, Leopold JA, Gimbrone MA Jr, Alexander RW. Short- and long-term interactions of endothelium and vascular smooth muscle in coculture: effects on cyclic GMP production. Proc Natl Acad Sci U S A. 1986;83(10):3552- 3556.
41. Tsai MC, et al. Shear stress induces synthetic-to-contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor alpha/delta activations by prostacyclin released by sheared endothelial cells. Circ Res. 2009; 105(5):471-480.
42. Rainger GE, Nash GB. Cellular pathology of atherosclerosis: smooth muscle cells prime cocultured endothelial cells for enhanced leukocyte adhesion. Circ Res. 2001;88(6):615-622.
43. Parenti A, Brogelli L, Filippi S, Donnini S, Ledda F. Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1. Cardiovasc Res. 2002; 55(1):201-212.
44. Keidar S, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109(18):2213-2220.
45. Couper LL, Bryant SR, Eldrup-Jorgensen J, Bredenberg CE, Lindner V. Vascular endothelial growth factor increases the mitogenic response to fibroblast growth factor-2 in vascular smooth muscle cells in vivo via expression of fms-like tyrosine kinase-1. Circ Res. 1997;81(6):932-939. (Pubitemid 27514942)
46. Osol G, et al. Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol. 2008;294(3):H1381-H1387.
47. Dagenais GR, et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation. 2001;104(5):522-526.
48. Sam F, et al. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology. 2010;151(1):322-331.
49. Nakamura T, et al. Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension. 2009;54(3):544-551.
50. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006; 20(9):1546-1548.
51. Park JK, et al. Growth arrest specific protein 6 participates in DOCA-induced target-organ damage. Hypertension. 2009;54(2):359-364.
52. Steinberg G, Khankin EV, Karumanchi SA. Angiogenic factors and preeclampsia. Thromb Res. 2009; 123 suppl 2:S93-S99.
53. Autiero M, et al. Role of PGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003;9(7):936-943.
54. Carmeliet P, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575-583.
55. Yano K, et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med. 2003;203(6):1447-1458. (Pubitemid 43877607)
56. Schnoes KK, et al. Rapid recruitment of temporally distinct vascular gene sets by estrogen. Mol Endocrinol. 2008;22(11):2544-2556.
57. Arriza JL, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237(4812):268-275.